U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07846267) titled 'Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma' on Sept. 22.
Brief Summary: This study will evaluate the efficacy and safety of cryoablation combined with Anlotinib plus TQB2868 in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Intrahepatic Cholangiocarcinoma
Intervention:
DRUG: Anlotinib
Anlotinib will be administered 10 mg orally daily for 2 weeks followed by a 1 week untreated recovery phase until documented disease progression, developme...